Genenta Science S.p.A (GNTA) Cash & Equivalents (2020 - 2025)

Genenta Science S.p.A has reported Cash & Equivalents for 6 years, with the latest figure at $32.8 million in Q4 2025.

• Quarterly Cash & Equivalents rose 142.21% year-over-year to $32.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32.8 million (up 142.21% YoY) and the FY2025 annual result came in at $32.8 million, up 142.21% from the prior year.
• Cash & Equivalents improved to $32.8 million in Q4 2025 per GNTA's latest filing, from $5.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $42.6 million in Q4 2021 and troughed at $19955.8 in Q2 2024.
• A 5-year average of $20.3 million and a median of $20.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 99.86% in 2023, then jumped 29263.58% in 2025.
• Over 5 years, Cash & Equivalents stood at $42.6 million in 2021, then dropped by 28.65% to $30.4 million in 2022, then slumped by 33.54% to $20.2 million in 2023, then plunged by 33.03% to $13.5 million in 2024, then soared by 142.21% to $32.8 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $32.8 million, $5.9 million, and $13.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.